Cargando…

Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions

PURPOSE: The antiarrhythmic drug amiodarone has a long half‐life of 60 days, which is often ignored in observational studies. This study aimed to investigate the impact of different exposure definitions on the association between amiodarone use and the risk of acute pancreatitis. METHOD: Using data...

Descripción completa

Detalles Bibliográficos
Autores principales: Hempenius, Mirjam, Groenwold, Rolf H.H., de Boer, Anthonius, Klungel, Olaf H., Gardarsdottir, Helga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916315/
https://www.ncbi.nlm.nih.gov/pubmed/31373736
http://dx.doi.org/10.1002/pds.4851
_version_ 1783480207506669568
author Hempenius, Mirjam
Groenwold, Rolf H.H.
de Boer, Anthonius
Klungel, Olaf H.
Gardarsdottir, Helga
author_facet Hempenius, Mirjam
Groenwold, Rolf H.H.
de Boer, Anthonius
Klungel, Olaf H.
Gardarsdottir, Helga
author_sort Hempenius, Mirjam
collection PubMed
description PURPOSE: The antiarrhythmic drug amiodarone has a long half‐life of 60 days, which is often ignored in observational studies. This study aimed to investigate the impact of different exposure definitions on the association between amiodarone use and the risk of acute pancreatitis. METHOD: Using data from the Dutch PHARMO Database Network, incident amiodarone users were compared to incident users of a different type of antiarrhythmic drug. Eighteen different definitions were applied to define amiodarone exposure, including dichotomized, continuous and categorized cumulative definitions with lagged effects to account for the half‐life of amiodarone. For each exposure definition, a Cox proportional hazards model was used to estimate the hazard ratio (HR) of hospitalization for acute pancreatitis. RESULTS: This study included 15,378 starters of amiodarone and 21,394 starters of other antiarrhythmic drugs. Adjusted HRs for acute pancreatitis ranged between 1.21−1.43 for dichotomized definitions of exposure to amiodarone, between 1.13‐1.22 for dose definitions (per DDD) and between 0.52‐1.72 for cumulative dose definitions, depending on the category. Accounting for lagged effects had little impact on estimated HRs. CONCLUSIONS: This study demonstrates the relative insensitivity of the association between amiodarone and the risk of acute pancreatitis against a broad range of different exposure definitions. Accounting for possible lagged effects had little impact, possibly because treatment switching and discontinuation was uncommon in this population.
format Online
Article
Text
id pubmed-6916315
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69163152019-12-17 Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions Hempenius, Mirjam Groenwold, Rolf H.H. de Boer, Anthonius Klungel, Olaf H. Gardarsdottir, Helga Pharmacoepidemiol Drug Saf Original Reports PURPOSE: The antiarrhythmic drug amiodarone has a long half‐life of 60 days, which is often ignored in observational studies. This study aimed to investigate the impact of different exposure definitions on the association between amiodarone use and the risk of acute pancreatitis. METHOD: Using data from the Dutch PHARMO Database Network, incident amiodarone users were compared to incident users of a different type of antiarrhythmic drug. Eighteen different definitions were applied to define amiodarone exposure, including dichotomized, continuous and categorized cumulative definitions with lagged effects to account for the half‐life of amiodarone. For each exposure definition, a Cox proportional hazards model was used to estimate the hazard ratio (HR) of hospitalization for acute pancreatitis. RESULTS: This study included 15,378 starters of amiodarone and 21,394 starters of other antiarrhythmic drugs. Adjusted HRs for acute pancreatitis ranged between 1.21−1.43 for dichotomized definitions of exposure to amiodarone, between 1.13‐1.22 for dose definitions (per DDD) and between 0.52‐1.72 for cumulative dose definitions, depending on the category. Accounting for lagged effects had little impact on estimated HRs. CONCLUSIONS: This study demonstrates the relative insensitivity of the association between amiodarone and the risk of acute pancreatitis against a broad range of different exposure definitions. Accounting for possible lagged effects had little impact, possibly because treatment switching and discontinuation was uncommon in this population. John Wiley and Sons Inc. 2019-08-02 2019-12 /pmc/articles/PMC6916315/ /pubmed/31373736 http://dx.doi.org/10.1002/pds.4851 Text en © 2019 The Authors. Pharmacoepidemiology & Drug Safety Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Reports
Hempenius, Mirjam
Groenwold, Rolf H.H.
de Boer, Anthonius
Klungel, Olaf H.
Gardarsdottir, Helga
Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions
title Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions
title_full Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions
title_fullStr Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions
title_full_unstemmed Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions
title_short Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions
title_sort amiodarone use and the risk of acute pancreatitis: influence of different exposure definitions
topic Original Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916315/
https://www.ncbi.nlm.nih.gov/pubmed/31373736
http://dx.doi.org/10.1002/pds.4851
work_keys_str_mv AT hempeniusmirjam amiodaroneuseandtheriskofacutepancreatitisinfluenceofdifferentexposuredefinitions
AT groenwoldrolfhh amiodaroneuseandtheriskofacutepancreatitisinfluenceofdifferentexposuredefinitions
AT deboeranthonius amiodaroneuseandtheriskofacutepancreatitisinfluenceofdifferentexposuredefinitions
AT klungelolafh amiodaroneuseandtheriskofacutepancreatitisinfluenceofdifferentexposuredefinitions
AT gardarsdottirhelga amiodaroneuseandtheriskofacutepancreatitisinfluenceofdifferentexposuredefinitions